Innovative VisiPlate® Glaucoma Device Successfully Implanted in First Patient During SAPPHIRE Trial
Avisi Technologies Marks Milestone in Glaucoma Treatment
In a significant advancement for glaucoma treatment, Avisi Technologies, Inc. has announced the successful implantation of their innovative device, VisiPlate®, in the first patient participating in the SAPPHIRE clinical trial. This landmark surgery took place at the Sacramento Eye Consultants in California, performed by the renowned Dr. Kiersten Snyder.
A Pioneering Approach to Glaucoma Management
The SAPPHIRE trial, officially designated as NCT07220876, is a multicenter, open-label study aimed at evaluating both the safety and effectiveness of the VisiPlate® aqueous shunt in patients diagnosed with Open-Angle Glaucoma (OAG). Glaucoma is notoriously known as one of the leading causes of irreversible blindness worldwide, impacting over 133 million individuals, highlighting the urgent need for breakthrough solutions in this field.
The VisiPlate® shunt is distinct in its design, utilizing a novel metamaterial that is notably thinner than a human hair. This unique feature not only enhances the longevity of the device but also promotes patient comfort and aesthetics. Importantly, the device incorporates multiple redundant microchannels designed to reduce the risk of blockage — a common challenge faced by existing glaucoma treatments. By facilitating controlled aqueous outflow, VisiPlate® aims to sustainably lower intraocular pressure (IOP), ultimately preserving vision for patients.
During the first surgery, Dr. Snyder expressed enthusiasm for the VisiPlate® technology: "The VisiPlate is a remarkable device showcasing a thin and flexible design for controlled aqueous outflow. It was also easy to install," she noted. This initial patient intervention marks a promising start for the trial, and positive feedback has already emerged highlighting the device's ease of implantation.
The SAPPHIRE Trial: Goals and Locations
The SAPPHIRE trial is set to involve around 65 patients across 13 medical sites in the United States, gathering crucial data to support future FDA applications. Current active trial sites include:
- - Arizona Advanced Eye Research in Glendale, Arizona
- - Glaucoma Associates of Texas in Dallas, Texas
- - ICON Eye Care in Grand Junction, Colorado
- - Sacramento Eye Consultants in Sacramento, California
- - The Eye Centers of Racine Kenosha in Wisconsin
As the trial continues to expand in 2026, it aims for a comprehensive evaluation of the VisiPlate® device’s safety and effectiveness, with the primary goal being a clinically significant reduction in diurnal IOP at the 12-month mark.
Aiming for Improved Patient Outcomes
Rui Jing Jiang, Founder and CEO of Avisi Technologies, emphasized the potential of the VisiPlate® device to enhance the quality of life for glaucoma patients. "Dr. Snyder's successful surgery progresses a needed solution for managing glaucoma and preserving vision," he stated, reflecting the company’s commitment to leading innovation in vision care.
Through this initiative, Avisi Technologies is not only addressing a critical gap in current glaucoma management strategies but also working towards fostering long-term relief and improved outcomes for affected individuals.
The Importance of Innovative Glaucoma Solutions
Presently, existing glaucoma treatments largely rely on medications, lasers, and surgical interventions that can pose challenges such as patient compliance and the risk of occlusion or scarring. These limits accentuate the pressing need for a sophisticated, long-lasting treatment like VisiPlate®, which is designed to mitigate such issues.
The future of glaucoma treatment looks promising with ongoing developments in technologies like VisiPlate®. As the understanding of glaucoma continues to evolve, innovative solutions are crucial for improving patients' lives and reducing the impact of this sight-threatening disease.
About Avisi Technologies
Founded with a commitment to advancing vision care, Avisi Technologies is a clinical-stage medical device company that specializes in creating cutting-edge ophthalmic solutions. Their portfolio features not only the VisiPlate® but also other pioneering products aimed at treating various ocular conditions, highlighting their transformational influence in the field of ophthalmology. For further information, visit avisitech.com.
Media Contact: Seth Harrington
Email: [email protected]
Stay updated on the progression of the SAPPHIRE clinical trial and the remarkable technologies being developed in the field of glaucoma care.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.